Ketamine-NAP Dosing to Raise ADNP With Lower Neurotoxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for methods to increase ADNP expression in cells and mammals with insufficient levels, particularly in conditions such as ADNP syndrome and autism, to address symptoms like intellectual disability, autism spectrum disorder, and other neurological conditions.
Innovation Solution
Administering ketamine and/or a combination of ketamine with NAP (ADNP-Derived Neuroprotective Peptide) to increase ADNP expression, using specific sub-anesthetic doses to avoid neurotoxic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If anesthetic doses of ketamine are administered to increase ADNP expression, then ADNP gene expression increases in the somatosensory cortex, but neurotoxic effects including apoptosis are induced
Solution Approach 1:
The patent changes the dosage parameter of ketamine from anesthetic doses to sub-anesthetic doses (e.g., 5-20 mg/kg body weight), which maintains the ability to induce ADNP gene expression while reducing neurotoxic effects. This parameter optimization resolves the contradiction between achieving therapeutic ADNP expression levels and avoiding harmful neurotoxicity.
Solution Approach 2:
The patent introduces NAP (Activity-Dependent Neuroprotective Peptide) as an intermediary substance that enhances ADNP expression when combined with sub-anesthetic ketamine doses. NAP acts as a mediator that amplifies the therapeutic effect of ketamine on ADNP expression while allowing the use of lower, less toxic ketamine doses, thus resolving the contradiction between efficacy and safety.
2Object-affected harmful factors
If sub-anesthetic doses of ketamine are used to reduce neurotoxicity, then neurotoxic effects are reduced, but ADNP expression induction may be insufficient
Solution Approach 1:
The patent combines sub-anesthetic ketamine with NAP in a combination therapy approach. This merging of two substances allows the system to achieve sufficient ADNP expression induction through synergistic effects, where NAP compensates for the reduced ADNP-inducing capacity of sub-anesthetic ketamine doses, while maintaining reduced neurotoxicity.
Solution Approach 2:
The patent creates a composite therapeutic approach using ketamine and NAP together. This composite therapy leverages the neuroprotective and ADNP-inducing properties of NAP to enhance the effectiveness of sub-anesthetic ketamine, resolving the contradiction between using lower doses for safety and maintaining sufficient therapeutic effect.
Data Source
AI summary
The invention is directed to a method of increasing the expression of Activity-Dependent Neuroprotector Protein (ADNP) in at least one mammalian cell showing insufficient ADNP expression levels, comprising administering to the at least one mammalian ceil an effective amount of ketamine or a combination of ketamine and ADNP-Derived Neuroprotective Peptide (NAP).